Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer The AvaALL Randomized Clinical Trial

Cesare Gridelli*, Javier Carpeno, Anne-Marie C. Dingemans, Frank Griesinger, Francesco Grossi, Corey Langer, Yuichiro Ohe, Konstantinos Syrigos, Nick Thatcher, Ashis Das-Gupta, Matt Truman, Margarita Donica, Vlatka Smoljanovic, Jaafar Bennouna

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


IMPORTANCE Bevacizumab treatment beyond progression has been investigated in breast and metastatic colorectal cancers. Avastin in All Lines Lung (AvaALL) is the first randomized phase 3 study of bevacizumab across multiple lines of treatment beyond progression in non-small cell lung cancer (NSCLC). OBJECTIVE To assess the efficacy and safety of continuous bevacizumab treatment beyond first progression in NSCLC. DESIGN, SETTING, AND PARTICIPANTS AvaALL was a randomized, open-label, phase 3b trial, conducted from 2011 to 2015 in 123 centers worldwide. Patients with nonsquamous NSCLC previously treated with first-line bevacizumab plus platinum-doublet chemotherapy and at least 2 cycles of bevacizumab maintenance were randomized (1:1) at first progression to receive bevacizumab plus standard of care (SOC) or SOC alone. INTERVENTIONS Patients received bevacizumab (7.5 or 15 mg/kg intravenously every 21 days) and/or investigator's choice of SOC. For subsequent lines, patients treated with bevacizumab received SOC with or without bevacizumab; the SOC arm received SOC only. MAIN OUTCOMES AND MEASURES The primary outcome was overall survival (OS). Secondary outcomes included progression-free survival from first to second (PFS2) and third progression (PFS3), time to second (TTP2) and third progression (TTP3), and safety. RESULTS Between June 2011 and January 2015, 485 patients (median age, 63.0 years [range, 26-84 years]; 293 [60.4%] male) were randomized. Median OS was not significantly longer with bevacizumab plus SOC vs SOC alone: 11.9(90% CI, 10.2-13.7) vs 10.2(90% CI, 8.6-11.9) months (hazard ratio [HR], 0.84; 90% CI, 0.71-1.00; P=.104). Median PFS2 was numerically longer with bevacizumab plus SOC vs SOC alone: 5.5(90% CI, 4.2-5.7) vs 4.0(90% CI, 3.4-4.3) months(HR, 0.83; 90% CI, 0.70-0.98; P=.06). Median PFS3 appeared longer with bevacizumab plus SOC vs SOC alone: 4.0(90% CI, 2.9-4.5) vs 2.6(90% CI, 2.3-2.9) months(HR, 0.63; 90% CI, 0.49-0.83), as did TTP2 and TTP3. Grade 3/4 adverse events were more frequent with bevacizumab plus SOC (186 [76.5%]) vs SOC alone (140 [60.3%]). No new safety signals were observed. CONCLUSIONS AND RELEVANCE The primary end point was not met; however, OS was underpowered according to initial statistical assumptions. Continued therapy beyond first progression led to improved PFS3 (but not PFS2), TTP2, and TTP3. Although a result with P=.06 for PFS2 would conventionally be considered significant at a specified 2-sided a of .10, in the absence of adjustments for multiplicity, this result could be a chance finding. No new safety signals were identified with bevacizumab treatment beyond progression.
Original languageEnglish
Article number183486
Number of pages5
JournalJAMA Oncology
Issue number12
Publication statusPublished - 1 Dec 2018
Event53rd American Society of Clinical Oncology Annual Meeting 2017 - McCormick Place , Chicago, United States
Duration: 2 Jun 20176 Jun 2017
Conference number: 53



Cite this